A Phase 2 Proof-of-Concept clinical trial to quantify myocardial manganese uptake rate by cardiovascular magnetic resonance imaging following mangafodipir trisodium administration in healthy volunteers and heart failure patients with preserved ejection fraction caused by hypertrophic cardiomyopathy or cardiac amyloidosis. - MNC001
Latest Information Update: 11 Sep 2025
At a glance
- Drugs Mangafodipir (Primary) ; Gadoterate-meglumine
- Indications Heart failure
- Focus Pharmacokinetics; Proof of concept
Most Recent Events
- 11 Sep 2025 New trial record